Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Influenza: new therapeutic perspectives]

F Bricaire1

  • 1Service de Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitié-Salpêtrière, Paris.

Presse Medicale (Paris, France : 1983)
|January 8, 1999
PubMed
Summary

Amantadine and rimantadine show limited effectiveness for influenza A treatment. New neuraminidase inhibitors like zanamivir offer better tolerance and symptom relief, but vaccination remains the primary prevention strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

French Society of ENT (SFORL) guidelines. Management of acute Bell's palsy.

European annals of otorhinolaryngology, head and neck diseases·2020
Same author

Reanimation : journal de la Societe de reanimation de langue francaise·2020
Same author

Chronic Lyme disease: A scam that should be condemned!

Medecine et maladies infectieuses·2019
Same author

Cost Effectiveness of Quadrivalent Influenza Vaccine Over Trivalent Vaccine in France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Proceedings of the 2nd seminar on emerging infectious diseases, December 7, 2012 – Current trends and proposals.

Revue d'epidemiologie et de sante publique·2014
Same author

Frequency and relevance of IgM intrathecal synthesis in multiple sclerosis.

European journal of neurology·2013

Area of Science:

  • Virology
  • Pharmacology

Context:

  • Amantadine and rimantadine are known agents against influenza A virus, but their clinical use is limited due to moderate efficacy and tolerance issues.
  • Diagnosis of influenza A can be challenging, further restricting the prophylactic use of these agents.

Purpose:

  • To review the efficacy and limitations of existing influenza antiviral agents and introduce novel compounds.
  • To evaluate new neuraminidase inhibitors for influenza treatment and prophylaxis.

Summary:

  • Amantadine and rimantadine have limited curative and prophylactic effects against influenza A, with variable tolerance.
  • Zanamivir, a neuraminidase inhibitor, is effective when administered nasally, reducing flu symptom duration and intensity with good tolerance.
  • GS4104, another neuraminidase inhibitor, shows promise in preclinical studies for influenza A and B.

Impact:

  • Vaccination remains the most effective influenza prevention method.
  • New antiviral compounds like zanamivir and GS4104 are considered complementary to vaccination strategies.
  • Further research into neuraminidase inhibitors may lead to improved influenza management options.

Related Experiment Videos